Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03906825 · ClinicalTrials.gov registry record · NA
Effect of CEAG on Inflammation and Endothelial Function
A NA study, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 80
- Enrollment target
NCT03906825 is a NA study that has completed, run by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center. The registered enrollment target is 80 participants.
The verdict
NCT03906825, a NA study, has completed, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
Study Summary
The purpose of the study is to look at the effect a dietary supplement called CEAG \[Curcuminoids, EPA (Omega-3), Astaxanthin and Gamma Linolenic Acid (GLA)\] has on inflammation and endothelial (inner layer of the blood vessels) function and whether it causes a lowering of blood pressure.The endothelium plays in an important role in blood pressure.
Interventions
- DIETARY_SUPPLEMENT placebo
- DIETARY_SUPPLEMENT CEAG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2018-05-17 |
| Est. Completion | 2018-08-13 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03906825
The ClinicalTrials.gov registry entry for NCT03906825 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, which has 55 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT03906825 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03906825 about?
NCT03906825 is a clinical study titled "Effect of CEAG on Inflammation and Endothelial Function". The purpose of the study is to look at the effect a dietary supplement called CEAG \[Curcuminoids, EPA (Omega-3), Astaxanthin and Gamma Linolenic Acid (GLA)\] has on inflammation and endothelial (inner layer of the blood vessels) function and whether it causes a lowering of blood pressure.The endoth...
What is the current status of trial NCT03906825?
This trial is currently completed. It is a NA study. The enrollment target is 80 participants. The study started on 2018-05-17. Estimated completion is 2018-08-13.
What interventions are being tested in trial NCT03906825?
The interventions under investigation include: placebo (DIETARY_SUPPLEMENT), CEAG (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03906825?
This trial is sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, which has 55 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.